Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31
July 01 2020 - 6:45AM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, will hold its second-quarter 2020 sales and earnings
conference call with institutional investors and analysts at 8:00
a.m. EDT on Friday, July 31. During the call, company executives
will provide an overview of Merck’s performance for the
quarter.
Investors, journalists and the general public may access a live
audio webcast of the call on Merck’s website at
http://investors.merck.com/investors/webcasts-and-presentations/default.aspx.
A replay of the webcast, along with the sales and earnings news
release and supplemental financial disclosures, will be available
at www.merck.com.
Institutional investors and analysts can participate in the call
by dialing (833) 353-0277 or toll free (469) 886-1947 and using ID
code number 2753878. Members of the media are invited to monitor
the call by dialing (833) 353-0277 or toll free (469) 886-1947 and
using ID code number 2753878. Journalists who wish to ask questions
are requested to contact a member of Merck’s Media Relations team
at the conclusion of the call.
About Merck
For more than 125 years, Merck, known as MSD outside of the
United States and Canada, has been inventing for life, bringing
forward medicines and vaccines for many of the world’s most
challenging diseases in pursuit of our mission to save and improve
lives. We demonstrate our commitment to patients and population
health by increasing access to health care through far-reaching
policies, programs and partnerships. Today, Merck continues to be
at the forefront of research to prevent and treat diseases that
threaten people and animals – including cancer, infectious diseases
such as HIV and Ebola, and emerging animal diseases – as we aspire
to be the premier research-intensive biopharmaceutical company in
the world. For more information, visit www.merck.com and connect
with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the recent global outbreak of novel coronavirus
disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
the company’s patents and other protections for innovative
products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200701005071/en/
Media Contact:
Pamela Eisele (267) 305-3558
Investor Contacts:
Peter Dannenbaum (908) 740-1037
Michael DeCarbo (908) 740-1807
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024